However, due to its single targeting that is typically combined with chemotherapeutic drugs, bevacizumab, when combined with platinum-based therapies, has a considerable PFS advantage in metastatic non-small cell lung cancer (NSCLC) (28).Tyrosine kinase inhibitors, such as sorafenib, sunitinib, and pazopanib, control angiogenesis by preventing the function of receptor tyrosine kinases that accelerate angiogenesis. Here, NTRK1 is linked to non-small cell lung carcinoma.